What this means
This trial will test whether a smartphone app with medicine reminders helps people take blood pressure pills. The study has not reported results yet, so we do not know if it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 60 and over · 100 older adults with mild memory problems, planned for a 16-week trial
- Where
- 2 sites, including Arizona, Illinois
The science
- Registered title
- bpMedManage: Digital Technology to Support Adherence to Hypertension Medications
- Trial ID
- NCT06307574 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Aging, Mild Cognitive Impairment, Hypertension
- What is tested
- bpMedManage
- Sponsor
- University of Arizona
- Ages
- 60 Years to no maximum
- Dates
- First posted Mar 13, 2024 · updated Oct 15, 2025
Registry summary
The purpose of the bpMedManage study is to rigorously test the efficacy of a smartphone technology to help improve high blood pressure medication adherence among older adults with mild cognitive impairment (MCI) in a 16-week randomized controlled trial. A total of 100 older adults will be recruited. There will be two treatment arms, bpMedManage-S and bpMedManage-P with 50 participants in each arm. Participants randomized into the bpMEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on an education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes on primary and secondary measures will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.
Sites (2)
- University of Arizona, Tucson, Arizona, United States
- University of Illinois, Urbana-Champaign, Champaign, Illinois, United States
